GenomeDx will have exclusive distribution rights for Guidance UGx and Guidance PRx in most of the US urology market, and Pathnostics will perform the testing at its CAP-accredited, CLIA-certified laboratory in Irvine, California.
“GenomeDx continues to drive the commercial adoption of genomic testing in urology through our proprietary Decipher classifier tests for prostate and bladder cancer and through strategic partnerships to expand our commercially available solutions,” said Doug Dolginow, M.D., chief executive officer of GenomeDx. “The management of UTIs and prostatitis is an area of great unmet medical need, and this partnership with Pathnostics allows us to provide a clinically superior solution to an antiquated technology in a way that is consistent with our focus on genomics and the urology market.”David Baunoch, Ph.D., chief scientific officer of Pathnostics, commented, “UTI and prostatitis cases often consist of complex polymicrobial infections that are commonly misclassified using traditional urine culture. Guidance testing allows for pathogen identification and characterization of antibiotic resistance days earlier than culture methodologies. We believe that Guidance pathogen identification and resistance testing improves patient outcomes.”
Dave Pauluzzi, chairman of Pathnostics, added, “Given the great commercial adoption we have had to date, with over 50,000 patients already tested, it is the right time to partner with GenomeDx to bring this technology to the broader urology community. GenomeDx is a leader in genomics in urology, and Guidance UGx and Guidance PRx are natural complements to GenomeDx’s Decipher portfolio of genomic solutions.”
EAU 2017: Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy
EAU 2017: The diverse genomic landscape of low-risk prostate cancer